Breast cancer cell lines, 361-TM and JIMT1-TM, exposed to multiple cycles of an anti-HER2 trastuzumab–maytansinoid ADC (TM-ADC) expressed 25% and 58% reduction of binding ability, respectively [84]. Here, ERBB2 is linked to breast carcinoma.